Precision medicine approach to treating neurological disorders
(NASDAQ: PRAX)
Investors 3
Mentions in press and media 16
| Date | Title | Description | Source |
| 05.04.2024 | Praxis Precision Medicines to Participate in Upcoming April ... | BOSTON, April 05, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinic... | einpresswi... |
| 05.03.2024 | Praxis Precision Medicines Provides Corporate Update and Rep... | - | globenewsw... |
| 08.01.2024 | Praxis Precision Medicines Provides Update on Advancing Clin... | Positive preliminary analysis of 15 mg cohort in the PRAX-628 study in epilepsy patients with Photo-... | einpresswi... |
| 15.06.2023 | Praxis Precision Medicines, Inc. Announces Pricing of $59.1 ... | - | globenewsw... |
| 07.02.2023 | Praxis Precision Medicines Provides Corporate Update and Rep... | /EIN News/ -- Ulixacaltamide (PRAX-944) Phase 2b Essential1 study topline results for essential trem... | einpresswi... |
| 06.01.2022 | Esker Therapeutics Announces Name Change to Alumis and Compl... | Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and i... | marketscre... |
| 16.08.2021 | Praxis Precision Medicines : Provides Corporate Update and R... | Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Resul... | marketscre... |
| 16.08.2021 | Praxis Precision Medicines : Provides Corporate Update and R... | Initiated PRAX-114 Phase 2 Acapella Study for adjunctive treatment of Major Depressive Disorder (MDD... | marketscre... |
| 16.08.2021 | Praxis Precision Medicines : Reports PRAX-114 Perimenopausal... | PRAX-114 showed rapid and marked improvements in menopausal and mood symptoms in Phase 2a PMD study ... | marketscre... |
| 12.05.2021 | PRAXIS PRECISION MEDICINES, INC. Praxis Precision Medicines... | Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2021 Financial Result... | marketscre... |
Show more